Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and multiple sclerosis:

Search results

Items: 1 to 20 of 241

1.

An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine.

Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O.

Pain Ther. 2019 Feb 5. doi: 10.1007/s40122-019-0114-4. [Epub ahead of print] Review.

PMID:
30721403
2.

Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Cannabinoids for Chronic Pain: Protocol for a Systematic Review.

Mohiuddin MM, Mizubuti G, Haroutounian S, Smith S, Campbell F, Park R, Gilron I.

JMIR Res Protoc. 2019 Jan 28;8(1):e11637. doi: 10.2196/11637.

3.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.

Patti F.

Neurodegener Dis Manag. 2019 Apr;9(2s):3-7. doi: 10.2217/nmt-2018-0049. Epub 2019 Jan 18.

PMID:
30657027
4.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.

Marková J.

Neurodegener Dis Manag. 2019 Apr;9(2s):9-13. doi: 10.2217/nmt-2018-0050. Epub 2019 Jan 18.

PMID:
30657024
5.

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Ziemssen T.

Neurodegener Dis Manag. 2019 Apr;9(2s):1-2. doi: 10.2217/nmt-2018-0048. Epub 2019 Jan 18.

PMID:
30657019
6.

Special Considerations and Assessment in Patients with Multiple Sclerosis.

Maitin IB, Cruz E.

Phys Med Rehabil Clin N Am. 2018 Aug;29(3):473-481. doi: 10.1016/j.pmr.2018.03.003. Epub 2018 May 8. Review.

PMID:
30626509
7.

Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G; CANALS Study Group.

Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X. Epub 2018 Dec 13.

PMID:
30554828
8.

Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal.

Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E.

Mult Scler Relat Disord. 2019 Jan;27:383-390. doi: 10.1016/j.msard.2018.11.022. Epub 2018 Nov 20.

PMID:
30502644
9.

Cannabis Therapeutics and the Future of Neurology.

Russo EB.

Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018.

10.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
11.

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice.

Gallily R, Yekhtin Z.

Inflammopharmacology. 2018 Oct 5. doi: 10.1007/s10787-018-0536-3. [Epub ahead of print]

PMID:
30291491
12.

Cannabinoid Delivery Systems for Pain and Inflammation Treatment.

Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F.

Molecules. 2018 Sep 27;23(10). pii: E2478. doi: 10.3390/molecules23102478. Review.

13.

A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.

Arroyo González R.

Expert Rev Neurother. 2018 Oct;18(10):785-791. doi: 10.1080/14737175.2018.1510772. Epub 2018 Sep 20.

PMID:
30235965
14.

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings.

Flachenecker P, Saccà F, Vila C.

Case Rep Neurol. 2018 Jul 12;10(2):169-176. doi: 10.1159/000490376. eCollection 2018 May-Aug.

15.

Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells.

Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS.

Front Immunol. 2018 Aug 3;9:1782. doi: 10.3389/fimmu.2018.01782. eCollection 2018.

16.

Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.

Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.

Clin Neuropharmacol. 2018 Sep/Oct;41(5):171-176. doi: 10.1097/WNF.0000000000000294.

PMID:
30024443
17.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

18.

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.

Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G.

Medicines (Basel). 2018 Jun 21;5(3). pii: E59. doi: 10.3390/medicines5030059.

19.
20.

Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.

Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.

Int J Neurosci. 2018 Sep 13:1-10. doi: 10.1080/00207454.2018.1481066. [Epub ahead of print]

PMID:
29792372

Supplemental Content

Loading ...
Support Center